FDA OKs new indication for AstraZeneca’s Brilinta
AstraZeneca’s Brilinta (ticagrelor) is now approved to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack.